Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
7.14 (USD) • At close December 23, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 9.216 | 4.695 | 1.064 | 8.752 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 2.06 | 1.897 | 1.846 | 1.834 | 1.391 | 1.151 | 2.682 | 2.576 | 2.169 | 1.132 | 0.809 | 0.582 | 0.467 | 0.274 | 0 | 0 | 0 | 0 |
| Gross Profit
| 9.216 | 2.635 | -0.833 | 6.906 | -1.834 | -1.391 | -1.151 | -2.682 | -2.576 | -2.169 | -1.132 | -0.809 | -0.582 | -0.467 | -0.274 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 1 | 0.561 | -0.783 | 0.789 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 27.616 | 25.995 | 25.129 | 25.289 | 28.306 | 29.076 | 26.755 | 24.868 | 21.342 | 20.936 | 17.915 | 18.13 | 15.115 | 14.637 | 9.273 | 9.863 | 5.472 | 4.855 | 3.815 |
| General & Administrative Expenses
| 8.127 | 9.282 | 8.985 | 7.728 | 8.662 | 8.145 | 7.504 | 7.621 | 7.02 | 6.295 | 6.387 | 5.257 | 4.753 | 3.486 | 2.231 | 2.073 | 0.914 | 0.541 | 0.478 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 8.127 | 9.282 | 8.985 | 7.728 | 8.662 | 8.145 | 7.504 | 7.621 | 7.02 | 6.295 | 6.387 | 5.257 | 4.753 | 3.486 | 2.231 | 2.073 | 0.914 | 0.541 | 0.478 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.96 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 35.743 | 35.277 | 34.114 | 33.017 | 36.968 | 37.221 | 34.259 | 32.489 | 28.362 | 27.231 | 24.302 | 23.387 | 19.868 | 18.123 | 11.504 | 11.936 | 6.386 | 5.396 | 4.293 |
| Operating Income
| -26.527 | -32.642 | -34.947 | -34.863 | -36.968 | -37.221 | -34.259 | -32.489 | -28.362 | -27.231 | -24.302 | -23.387 | -19.868 | -18.123 | -11.504 | -11.936 | -6.386 | -5.396 | -4.293 |
| Operating Income Ratio
| -2.878 | -6.953 | -32.845 | -3.983 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.739 | 2.584 | 3.062 | 1.589 | 2.254 | 2.233 | 2.221 | 1.707 | 1.044 | 0.762 | 0.37 | -0.053 | 0.031 | -0.282 | -0.772 | -7.72 | -0.172 | 0.032 | -0.009 |
| Income Before Tax
| -23.788 | -30.058 | -31.885 | -33.274 | -34.714 | -34.988 | -32.038 | -30.782 | -27.318 | -26.469 | -23.932 | -23.44 | -19.837 | -18.405 | -12.276 | -19.656 | -6.558 | -5.364 | -4.302 |
| Income Before Tax Ratio
| -2.581 | -6.402 | -29.967 | -3.802 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.071 | 0.252 | 0.083 | -0.022 | -0.17 | 0.19 | -2.221 | -1.707 | -1.044 | -0.762 | -0.37 | -0.756 | -0.613 | 0.282 | -0.188 | 0.04 | 0.172 | -0.032 | 0.003 |
| Net Income
| -23.859 | -30.31 | -31.968 | -33.252 | -34.884 | -35.178 | -29.817 | -29.075 | -26.274 | -25.707 | -23.562 | -23.44 | -19.837 | -18.405 | -12.276 | -19.656 | -6.558 | -5.364 | -4.302 |
| Net Income Ratio
| -2.589 | -6.456 | -30.045 | -3.799 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.29 | -0.43 | -0.53 | -0.58 | -0.7 | -0.71 | -0.6 | -0.59 | -0.56 | -0.55 | -0.51 | -0.51 | -0.43 | -3.63 | -0.29 | -0.9 | -0.3 | -0.25 | -0.2 |
| EPS Diluted
| -0.29 | -0.43 | -0.53 | -0.58 | -0.7 | -0.71 | -0.6 | -0.59 | -0.56 | -0.55 | -0.51 | -0.51 | -0.43 | -3.63 | -0.29 | -0.9 | -0.3 | -0.25 | -0.2 |
| EBITDA
| -24.424 | -30.582 | -33.05 | -33.017 | -35.133 | -35.83 | -33.108 | -31.419 | -27.329 | -26.342 | -23.549 | -22.578 | -19.286 | -17.656 | -11.23 | -11.713 | -6.215 | -5.324 | -4.228 |
| EBITDA Ratio
| -2.65 | -6.514 | -31.062 | -3.773 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |